BioCentury | Feb 27, 2012
Company News

Critical Pharmaceuticals, University of Nottingham deal

...osteoporosis in postmenopausal women. Asahi Kasei Pharma Corp. (Tokyo, Japan) markets teriparatide in Japan as Teribone...
BioCentury | Dec 5, 2011
Company News

Asahi Kasei sales and marketing update

...Asahi launched Teribone teriparatide in Japan to treat osteoporosis in patients with a high risk of...
...use Zosano's ZP Patch microprojection delivery technology to develop and commercialize a transdermal formulation of Teribone...
BioCentury | Oct 17, 2011
Company News

Zosano, Asahi Kasei Pharma deal

...delivery technology to develop and commercialize a transdermal formulation of Asahi's once-weekly subcutaneous osteoporosis drug Teribone...
BioCentury | Oct 11, 2011
Company News

Asahi, Zosano in deal for transdermal osteoporosis drug

...delivery technology to develop and commercialize a transdermal formulation of Asahi's once-weekly subcutaneous osteoporosis drug Teribone...
Items per page:
1 - 4 of 4